Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / BARDA

BARDA

Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay
Biotechnology | COVID-19 | Diagnostics | FDA | Infectious Disease

Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay

On Feb. 18, 2025, Hologic announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance…

Read More Hologic Announces FDA Clearance of Aptima SARS-CoV-2 AssayContinue

U.S. awarded Moderna $590 million for bird flu vaccine development
Biotechnology | Infectious Disease | Influenza | NIH | Vaccine

U.S. awarded Moderna $590 million for bird flu vaccine development

On Jan. 17, 2025, The U.S. government announced it had awarded Moderna $590 million to advance the development…

Read More U.S. awarded Moderna $590 million for bird flu vaccine developmentContinue

BARDA Awards $375 million to develop COVID-19 pre-exposure prophylaxis 
Biotechnology | COVID-19 | Infectious Disease | NIH | Therapeutics | Vaccine

BARDA Awards $375 million to develop COVID-19 pre-exposure prophylaxis 

On Jan. 16, 2025, Shionogi Inc. has been awarded a $375 million project agreement through the Rapid Response…

Read More BARDA Awards $375 million to develop COVID-19 pre-exposure prophylaxis Continue

HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity
Biotechnology | Chemical | FDA | NIH | Radiology | Therapeutics

HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity

On Oct. 28, 2024, HOPO Therapeutics announced that it has been awarded a contract valued at up to…

Read More HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal ToxicityContinue

RedHill Biopharma Secured U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
Biotechnology | FDA | Infectious Disease | Therapeutics

RedHill Biopharma Secured U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

On Oct. 14, 2024, RedHill Biopharma announced that the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA)…

Read More RedHill Biopharma Secured U.S. Government Funding through BARDA to Advance Opaganib for Ebola TreatmentContinue

Moderna Received $176 million Award through BARDA to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
Biotechnology | Infectious Disease | Influenza | Vaccine

Moderna Received $176 million Award through BARDA to Accelerate Development of mRNA-based Pandemic Influenza Vaccine

On Jul. 2, 2024, Moderna announced a project award of $176 million through the Rapid Response Partnership Vehicle…

Read More Moderna Received $176 million Award through BARDA to Accelerate Development of mRNA-based Pandemic Influenza VaccineContinue

Emergent received $75 million contract option from BARDA to procure doses of CYFENDUS (Anthrax Vaccine)
Biotechnology | FDA | Infectious Disease | Vaccine

Emergent received $75 million contract option from BARDA to procure doses of CYFENDUS (Anthrax Vaccine)

On Nov. 28, 2023, Emergent BioSolutions announced that the Biomedical Advanced Research and Development Authority (BARDA) within the…

Read More Emergent received $75 million contract option from BARDA to procure doses of CYFENDUS (Anthrax Vaccine)Continue

Vir Biotechnology awarded BARDA funding to support development of antibody platform technologies for global infectious disease threats
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Vir Biotechnology awarded BARDA funding to support development of antibody platform technologies for global infectious disease threats

On Oct. 3, 2023, Vir Biotechnology announced that the Biomedical Advanced Research and Development Authority (BARDA), part of…

Read More Vir Biotechnology awarded BARDA funding to support development of antibody platform technologies for global infectious disease threatsContinue

Gritstone Bio awarded $433 Mmillion BARDA contract to conduct comparative phase 2b study evaluating next-generation vaccine candidate for COVID-19
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Gritstone Bio awarded $433 Mmillion BARDA contract to conduct comparative phase 2b study evaluating next-generation vaccine candidate for COVID-19

On Sept. 27, 2023, Gritstone bio announced that it was awarded a contract by the Biomedical Advanced Research…

Read More Gritstone Bio awarded $433 Mmillion BARDA contract to conduct comparative phase 2b study evaluating next-generation vaccine candidate for COVID-19Continue

Emergent BioSolutions awarded 10-Year BARDA contract valued at  $704 million for Ebanga treatment for Ebola
Biotechnology | Infectious Disease | Therapeutics | Vaccine

Emergent BioSolutions awarded 10-Year BARDA contract valued at $704 million for Ebanga treatment for Ebola

On Jul. 31, 2023, Emergent BioSolutions announced that it was awarded a 10-year contract by the Biomedical Advanced…

Read More Emergent BioSolutions awarded 10-Year BARDA contract valued at $704 million for Ebanga treatment for EbolaContinue

Texas Biomed added to national readiness and preparedness network
Biotechnology | Diagnostics | Infectious Disease | Therapeutics

Texas Biomed added to national readiness and preparedness network

On Dec. 13, 2022, Texas Biomed announced that it had been designated as a prime contractor by the…

Read More Texas Biomed added to national readiness and preparedness networkContinue

Hologic announced contract with BARDA to support IVD approval of COVID assays
Biotechnology | COVID-19 | Diagnostics | Infectious Disease

Hologic announced contract with BARDA to support IVD approval of COVID assays

On Nov. 2, 2022, Hologic announced that it had been awarded a $19 million contract from the Biomedical…

Read More Hologic announced contract with BARDA to support IVD approval of COVID assaysContinue

U.S. Department of Health and Human Services funded U.S.-based production of Smallpox and Mpox vaccine
Biotechnology | Infectious Disease | Vaccine

U.S. Department of Health and Human Services funded U.S.-based production of Smallpox and Mpox vaccine

On Aug. 29, 2022, the U.S. Department of Health and Human Services (HHS) announced it had provided approximately…

Read More U.S. Department of Health and Human Services funded U.S.-based production of Smallpox and Mpox vaccineContinue

OraSure received $13.6 million from BARDA to support InteliSwab COVID-19 rapid test 510(k) Clearance and CLIA Waiver
Biotechnology | COVID-19 | Diagnostics | FDA | Infectious Disease

OraSure received $13.6 million from BARDA to support InteliSwab COVID-19 rapid test 510(k) Clearance and CLIA Waiver

On Sept. 23, 2021, OraSure Technologies and the Biomedical Advanced Research Development Authority (BARDA) announced up to $13.6…

Read More OraSure received $13.6 million from BARDA to support InteliSwab COVID-19 rapid test 510(k) Clearance and CLIA WaiverContinue

Paratek announced first BARDA Project BioShield procurement of NUZYRA (omadacycline)
Biotechnology | Infectious Disease | Vaccine

Paratek announced first BARDA Project BioShield procurement of NUZYRA (omadacycline)

On Jun. 29, 2021, Paratek Pharmaceuticals announced it had delivered the first procurement of NUZYRA to the Biomedical…

Read More Paratek announced first BARDA Project BioShield procurement of NUZYRA (omadacycline)Continue

U.S. Government purchased additional 200 million doses of Moderna’s COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

U.S. Government purchased additional 200 million doses of Moderna’s COVID-19 vaccine

On Jun. 16, 2021, Moderna announced that the U.S. government had purchased an additional 200 million doses of…

Read More U.S. Government purchased additional 200 million doses of Moderna’s COVID-19 vaccineContinue

HHS launched first venture capital partnership to develop transformative technologies to combat future pandemics
Biotechnology | COVID-19 | Infectious Disease | NIH | Therapeutics | Vaccine

HHS launched first venture capital partnership to develop transformative technologies to combat future pandemics

On Jun. 1, 2021, the U.S. Department of Health and Human Services (HHS) unveiled a new type of…

Read More HHS launched first venture capital partnership to develop transformative technologies to combat future pandemicsContinue

Emergent announced support of manufacturing capacity expansion for Johnson & Johnson’s COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Emergent announced support of manufacturing capacity expansion for Johnson & Johnson’s COVID-19 vaccine

On Apr. 4, 2021, Emergent BioSolutions announced it had received a contract modification to increase the original task…

Read More Emergent announced support of manufacturing capacity expansion for Johnson & Johnson’s COVID-19 vaccineContinue

ContraFect announced BARDA contract award for up to $868 million for antibiotic-resistant infections
Biotechnology | Infectious Disease | Therapeutics

ContraFect announced BARDA contract award for up to $868 million for antibiotic-resistant infections

On Mar. 11, 2021, ContraFect announced that it had been awarded a cost-share contract from the Biomedical Advanced…

Read More ContraFect announced BARDA contract award for up to $868 million for antibiotic-resistant infectionsContinue

Luminex submitted joint SARS-CoV-2 and Flu/RSV respiratory panel to FDA for Emergency Use Authorization
Biotechnology | COVID-19 | FDA | Infectious Disease | Vaccine

Luminex submitted joint SARS-CoV-2 and Flu/RSV respiratory panel to FDA for Emergency Use Authorization

On Mar. 10, 2021, Luminex announced that it had submitted an Emergency Use Authorization application to the U.S….

Read More Luminex submitted joint SARS-CoV-2 and Flu/RSV respiratory panel to FDA for Emergency Use AuthorizationContinue

Merck announced partnership to produce Johnson & Johnson’s COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Medicine | Vaccine

Merck announced partnership to produce Johnson & Johnson’s COVID-19 vaccine

On Mar. 2, 2021, Merck announced multiple agreements to support efforts to expand manufacturing capacity and supply of…

Read More Merck announced partnership to produce Johnson & Johnson’s COVID-19 vaccineContinue

Luminex received BARDA funding to support development and validation of test combining SARS-CoV-2 and Flu/RSV respiratory pane
Biotechnology | COVID-19 | FDA | Infectious Disease | Influenza | Therapeutics

Luminex received BARDA funding to support development and validation of test combining SARS-CoV-2 and Flu/RSV respiratory pane

On Feb. 19, 2021, Luminex announced that it had received $11.3 million in funding from the Biomedical Advanced…

Read More Luminex received BARDA funding to support development and validation of test combining SARS-CoV-2 and Flu/RSV respiratory paneContinue

Humanigen announced BARDA contract and Expansion of CRADA with U.S. Government for COVID-19
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

Humanigen announced BARDA contract and Expansion of CRADA with U.S. Government for COVID-19

On Jan. 22, 2021, Humanigen announced an expansion to the Cooperative Research and Development Agreement (CRADA) that the…

Read More Humanigen announced BARDA contract and Expansion of CRADA with U.S. Government for COVID-19Continue

ImmunityBio’s hAd5 T-Cell COVID-19 vaccine candidate showed complete protection of airways
Biotechnology | COVID-19 | Infectious Disease | Vaccine

ImmunityBio’s hAd5 T-Cell COVID-19 vaccine candidate showed complete protection of airways

On Dec. 10, 2020, ImmunityBio announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates…

Read More ImmunityBio’s hAd5 T-Cell COVID-19 vaccine candidate showed complete protection of airwaysContinue

Humanigen announced CRADA agreement with U.S. government to develop lenzilumab for COVID-19
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

Humanigen announced CRADA agreement with U.S. government to develop lenzilumab for COVID-19

On Nov. 6, 2020, Humanigen announced that it had entered into a Cooperative Research and Development Agreement (CRADA)…

Read More Humanigen announced CRADA agreement with U.S. government to develop lenzilumab for COVID-19Continue

Mesa Biotech received additional $13 million from HHS to develop 30 minute SARS-CoV-2 & Flu A/Flu B test
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza

Mesa Biotech received additional $13 million from HHS to develop 30 minute SARS-CoV-2 & Flu A/Flu B test

On Nov. 6, 2020, Mesa Biotech announced it had been awarded a contract up to $13 million from…

Read More Mesa Biotech received additional $13 million from HHS to develop 30 minute SARS-CoV-2 & Flu A/Flu B testContinue

Moderna completed enrollment of phase 3 COVE study of mRNA vaccine against COVID-19
Biotechnology | COVID-19 | FDA | Infectious Disease | Vaccine

Moderna completed enrollment of phase 3 COVE study of mRNA vaccine against COVID-19

On Oct. 22, 2020, Moderna announced that it had completed enrollment of 30,000 participants for the Phase 3…

Read More Moderna completed enrollment of phase 3 COVE study of mRNA vaccine against COVID-19Continue

BARDA reselected ICON as preferred partner to help strengthen U.S. emergency preparedness and response
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

BARDA reselected ICON as preferred partner to help strengthen U.S. emergency preparedness and response

On Oct. 19, 2020, ICON announced that it had been re-selected by the Biomedical Advanced Research and Development…

Read More BARDA reselected ICON as preferred partner to help strengthen U.S. emergency preparedness and responseContinue

NIH RADx initiative advanced six new COVID-19 testing technologies
Biotechnology | COVID-19 | Infectious Disease | NIH | Therapeutics

NIH RADx initiative advanced six new COVID-19 testing technologies

On Oct. 6, 2020, the National Institutes of Health (NIH), working in collaboration with the Biomedical Advanced Research…

Read More NIH RADx initiative advanced six new COVID-19 testing technologiesContinue

Moderna announced supply agreement with U.S. Government for initial 100 million doses of mRNA vaccine against COVID-19
Biotechnology | Infectious Disease | Vaccine

Moderna announced supply agreement with U.S. Government for initial 100 million doses of mRNA vaccine against COVID-19

On Aug. 11, 2020, Moderna announced that the U.S. government had secured 100 million doses of mRNA-1273. The…

Read More Moderna announced supply agreement with U.S. Government for initial 100 million doses of mRNA vaccine against COVID-19Continue

Page navigation

1 2 Next PageNext
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search